[AMDS/OMS publie un nouveau document montre l'évolution des prix.CB]
Transaction Prices for Antiretroviral Medicines and HIV Diagnostics
from 2004 to September 2008
GPRM - Global Price Reporting Mechanism
October 2008
http://www.who.int/hiv/amds/GPRMsummaryReportOct2008.pdf
Contents
Abbreviations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . 5
Table 1 : Median transaction price of first-line ARV medicines for adult
treatment per
patient per year (US$/ppy) at a WHO recommended adult defined daily dose
(DDD) . . . . . . . 6
Table 2: Median transaction price of second-line ARV medicines (US$/ppy) for
adult
treatment at a WHO recommended adult DDD . . . . . . . . . . . . . . . . . .
. . . . . . . . 9
Table 3: Median transaction price of ARV medicines (US$/ppy) for paediatric
treatment
(infant weighing 5 kg) at a WHO recommended paediatric DDD. . . . . . . . .
. . . . . . . . 12
Table 4: Median transaction price of ARV medicines (US$/ppy) for paediatric
treatment
(infant weighing 10 kg) at a WHO recommended paediatric DDD. . . . . . . . .
. . . . . . . 15
Table 5: Median transaction price (US$) of smallest unit of rapid tests . .
. . . . . . . . . . . . . 18
Table 6: Median transaction price of ELISA and confirmatory tests in 2007
and 2008 (US$) . . . 19
Fig. 1a: The price trend for the most commonly used first-line regimens in
low-income countries
(LIC) for adult patients.. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 20
Fig. 1b: The price trend for the most commonly used first-line regimens in
lower middle-income
countries (LMIC) for adult patients. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 20
Fig. 1c: The price trend for the most commonly used first-line regimens in
upper middle-income
countries (UMIC) for adult patients.. . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 21
Fig. 2a: The price trend for the most commonly used second-line regimens in
low-income countries
(LIC) for adult patients.. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 22
Fig. 2b: The price trend for the most commonly used second-line regimens in
lower middle-income
countries (LMIC) for adult patients . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 22
Fig. 2c: The price trend for the most commonly used second-line regimens in
upper middle-income
countries (UMIC) for adult patients.. . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 23
Fig. 3a: The price trend for the most commonly used first-line regimens for
paediatric patients
(infant of 5 kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . 24
Fig. 3b: The price trend for the most commonly used second-line regimens for
paediatric patients
(infant of 5 kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . 24
Fig. 4a: The price trend for the most commonly used first-line regimens for
paediatric patients
(infant of 10 kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 25
Fig. 4b: The price trend for the most commonly used second-line regimens for
paediatric patients
(infant of 10 kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 25
Figure 5: Number of HIV rapid test (2004 - 2007) (millions) . . . . . . . .
. . . . . . . . . . . 26
Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . 26
Formulations for adult first-line regimens... 26
Formulations for adult second-line regimens.. 26
Paediatric formulations........................................ 27
HIV
diagnostics.................................................................
28
Conclusions... 29
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . 30